|
|
|
|
| |
| Fox Chase Cancer Center |
| |
Fox Chase Cancer Center's mission is to reduce the burden of human cancer. Fox Chase's activities include basic, clinical and prevention research; detection and treatment of cancer; and community outreach programs.
Fox Chase Cancer Center is an independent, nonprofit institution formed in 1974 by the union of American Oncologic Hospital (the nation's first cancer hospital, established in 1904) and the Institute for Cancer Research (founded in 1927).
Fox Chase's 100-bed hospital is one of the few facilities in the country devoted entirely to cancer care. About 170 clinical trials of new prevention, diagnostic and treatment techniques are under way at any one time. Fox Chase is also involved in developing trials to test new agents that may prevent cancer in high-risk individuals. Combining research in many disciplines with patient care enables Fox Chase to translate new research findings into medical applications that may become models for improved cancer care. |
 |
| |
Fox Chase is structured around three divisions: medical science, basic science and population science.
- Medical science is committed to providing excellent patient care and conducting a broad-based program of clinical
research, including clinical trials.
- The division of basic science is renowned worldwide for its work in understanding both normal and abnormal
cell growth and development
- The goal of the division of population science is to identify people at high risk of cancer and to develop strategies
to reduce these risks through programs of prevention and early detection.
Fox Chase has 70 robust basic science programs ranging from labs focusing on the most fundamental cellular problems to translational research. These programs are complemented with superior core facilities allowing researchers to spend less time on repetitive tasks, and more time designing and completing experiments. Our programs include:
|
|
| |
Institutional Contacts:
For more information, visit our website at www.fccc.edu |
|
| |
RNAi Global Principal Investigators:
| |
Timothy J. Yen, Ph.D.
Genome Stability Working Group Leader
Senior Member — Basic Science Division
Email
Louis M. Weiner, M.D.
Chairman, Medical Oncology
Vice President, Translational Research
Senior Member — Medical Science Division
Developmental Therapeutics Group Leader
Email
Anna Skalka, Ph.D.
Senior Vice President, Basic Science Division
Senior Member — Basic Science Division
Email |
Alfonso Bellacosa, M.D., Ph.D.
Member — Population Science Division
Email
Dominique Broccoli, Ph.D.
Member — Basic Science Division
Email
Yishihiro Matsumoto, Ph.D.
Member — Basic Science Division
Email
Hong Yan, Ph.D.
Member — Basic Science Division
Email
Peter D. Adams, Ph.D.
Member — Basic Science Division
Email
Margret Einarson, Ph.D.
Translational Facility Manager
Email |
|
|
|
| |
|
|
|
|
